

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/00, 38/03, 38/04, 38/18, 38/22, 38/27, 38/30	A1	(11) International Publication Number: WO 98/42361 (43) International Publication Date: 1 October 1998 (01.10.98)
(21) International Application Number: PCT/US98/05978 (22) International Filing Date: 24 March 1998 (24.03.98) (30) Priority Data: 08/824,523 26 March 1997 (26.03.97) US (71)(72) Applicants and Inventors: SPENCER, E., Martin [US/US]; 505 Ortega Street, San Francisco, CA 94122 (US). LUE, Tom [US/US]; 1151 Barroilhet Drive, Hillsborough, CA 94010 (US). (74) Agent: WEITZ, David, J.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304-1050 (US).	(81) Designated States: European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: HUMAN ERECTILE DYSFUNCTION AND METHODS OF TREATMENT (57) Abstract This invention is a method for treating human erectile dysfunction using therapeutic amounts of human growth hormone (GH) administered systemically. Severing the parasympathetic nerves that regulate the erectile function during the course of surgery produces erectile dysfunction. Damage to these nerves by diseases such as diabetes mellitus and alcoholism and during aging may also produce erectile dysfunction. GH stimulates the regeneration of severed parasympathetic nerves that regulate the erectile function restoring potency. GH may act directly or by stimulating the production of insulin-like growth factor-I (IGF-I). The combination of GH plus IGF (with or without one of the IGF binding proteins) may provide a better response than GH alone.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

HUMAN ERECTILE DYSFUNCTION AND METHODS OF TREATMENT

Field of the invention: This invention relates to human erectile dysfunction (male impotence) and methods to treat this condition.

Background

5

Physiology of the erectile response. The engorgement of two erectile bodies in the penis (corpora cavernosa) with blood produces the erection. An erection occurs when parasympathetic nervous impulses simultaneously relax the arterial supply to the corpora and the smooth muscle cells in the corpora allowing blood to flow into the
10 sinuses (spaces) of the corpora. Engorgement with blood compresses the venous outflow against the rigid fibrous membrane (tunica albuginea) around the corpora trapping the blood within the erectile bodies producing the erection.

Etiology of erectile dysfunction. Erectile dysfunction is defined as the inability
15 to achieve an erection sufficient for intercourse. The cause of erectile dysfunction (impotence) can be defined by diagnostic modalities, such as color duplex sonography, administration of vasoactive agents into one of the two corpora cavernosa (the erectile bodies in the penis), nocturnal penile tumescence testing, and measurement of the pressure in the cavernosa (cavernosometry) Lue, T. F. and Tanagho, E. A., "Physiology
20 of erection and pharmacologic management of impotence," J. Urol. 137, pp 829832, (1987). Erectile dysfunction can be defined as (1) psychogenic, (2) neurogenic, (3) hormonal, (4) vascular, (5) cavernosal, (6) drug induced or (7) a combination of these etiologic elements. The majority of patients with erectile dysfunction suffer from aging changes of the neurovascular supply of the penis and the pelvic ganglia. Lue T. F.,
25 "Physiology of penile erection and pathophysiology of impotence", in Campbell's Urology, Sixth Edition, eds. Walse P. C. et al. (W. B. Saunders 1992) pp. 707-728.

Therapy. Lue T. F., "Physiology of penile erection and pathophysiology of impotence", in Campbell's Urology, Sixth Edition, eds. Walsh P. C. Et al. (W. B. Saunders 1992) pp. 707-728. Psychosexual therapy or counseling is the preferred treatment for patients with psychogenic erectile dysfunction. Testosterone replacement is effective for patients with testosterone deficiency. Change or discontinuing offending medications or illicit drugs may help the appropriate patients. Oral or topical medications for erectile dysfunction have not been very helpful. Intraurethral alprostadil provides some, but not complete improvement of the erectile response in approximately 50% of patients. The penile prostheses include a wide arrange of implantable, commandable and nearphysiologic devices to permit intercourse. Self-injection into the cavernosa uses several agents such as papaverine, phentolamine and alprostadil, or a combination of drugs. Vacuum and compression devices provide additional options to the patient and physician. Arterial reconstruction and venous surgery are effective only for young patients with localized vascular problems. No effort has been made to stimulate nerve regeneration as a way to prevent or cure impotence. (Alternative, there is no therapy to stimulate nerve regeneration as a way to prevent or cure impotence.)

The treatments described above may help the patient to achieve a better erection and an erection which will, temporarily, last longer. Except for penile revascularization and testosterone replacement, other current impotence treatments are non-specific and do not offer a cure or prevention. Unfortunately, only a very small number of patients suffer from hormonal deficiency or a curable penile vascular disease. Therefore, the vast majority of patients require either a permanent penile implant or treatment prior to sexual intercourse with intracavernous injection, intraurethral injection, or a vacuum device. Since there are drawbacks to all these therapies, most patients have not availed themselves of treatment. Therefore, a more physiologic approach to either prevent or cure erectile dysfunction is highly desirable. To date no one has successfully addressed restoration of potency secondary to radical pelvic surgery for prostatic and urinary bladder cancer and other surgeries that may damage the pelvic parasympathetic innervation of the penis such as vascular and colo-rectal surgery.

Growth Hormone. Human growth hormone (also referred to as somatotropin and "GH") is a growth-promoting, anabolic polypeptide hormone of approximately 21,400 daltons. Jameson, J. L., "Growth Hormone" in Cecil Textbook Of Medicine, eds. Bennett, J. C. And Plum, F. (W. B. Saunders 1996) pp. 1210-1212. GH is synthesized
5 in the pituitary gland and released into the circulation. Some of the GH circulating in plasma is bound to a binding protein which in humans is the extracellular domain of the cell surface GH receptor. The plasma level of GH can be determined by radioimmunoassay, ELISA, or radioreceptor assay. GH secretion is regulated positively and negatively by peptides released from the hypothalamus, GH releasing factor (GHRF)
10 and somatotropin release inhibiting factor (SRIF), respectively, and is feedback inhibited by insulin-like growth factor-I (also referred to as somatomedin-C and IGF-I).

GH stimulates: a) human and other animal growth, b) the growth of various organs and tissues in the body that include skeletal tissues, c) the synthesis of IGF-I,
15 d) cellular amino acid uptake and protein synthesis (while decreasing protein degradation), e) wound healing in elderly healthy subjects, f) immune functions, g) lipolysis (the breakdown of fat), h) the secretion of insulin, and i) the resistance of tissues to insulin. Papadakis, M. A. et al., "Effect Of Growth Hormone Replacement On Wound Healing In Healthy Older Men," Wound Rep. Reg. 4, p 421 (1996). GH has not
20 been reported to stimulate parasympathetic nerve regeneration.

IGF-I mediates many of the growth-promoting effects of GH on tissues and mediates many of the anabolic actions of GH. Schlechter, N. L. et al., "Evidence Suggesting That The Direct Growth-promoting Effect Of Growth Hormone On Cartilage
25 *in vivo* Is Mediated By Local Production Of Somatomedin," Proc. Natl. Acad. Sciences 83, p. 7932 (1986). IGF-I has a quantitatively different degree of action than GH on certain tissues and has an additive effect on body growth when administered with GH *in vivo* in animals deficient in GH. Fielder, P. J. et al., "Differential Long-term Effects Of Insulin-like Growth Factor-I (IGF-I) Growth Hormone (GH), and IGF-I plus
30 GH On Body Growth And IGF Binding Proteins In Hypophysectomized Rats,"

Endocrinology 137, p. 1913 (1996). IGF-I has been reported to stimulate guanylyl cyclase to increase tissue levels of cGMP in lymphocytes and chondrocytes. Spencer, E. M. et al., "The Effect Of Somatomedin On Adenylyl Cyclase And Guanylyl Cyclase Activity In Various Tissues," in Somatomedins And Growth, eds. Giordano, G. et al., (Academic Press 1979) p 37; cGMP is known to be a mediator for smooth muscle actions involved in the erectile response.

IGF-I action is also regulated by a class of 6 circulating specific binding proteins, the most abundant being IGF binding protein-3, also known as "IGFBP-3." Shimasaki, S. et al., "Isolation And Molecular Characterization Of Three Novel Insulin-like Growth Factor Binding Proteins (IGFBP-4, 5 and 6)" in Modern Concepts Of Insulin-Like Growth Factors, ed. Spencer, E. M., (Elsevier, 1991) p. 343-358; Spencer, E. M. et al., "Insulin-like Growth Factor Binding Protein-3 Is Present In The α -Granules Of Platelets," Endocrinology 132, p. 996 (1993). After association with IGF-I, the action of IGF-I is generally inhibited by IGFBPs, but under certain conditions the complex of IGF-I with an IGFBP may be stimulatory. Sommer, A. et al., "Molecular Genetics And Actions Of Recombinant Insulin-like Growth Factor Binding Protein-3 in Modern Concepts Of Insulin-Like Growth Factors, ed. Spencer, E. M., (Elsevier 1991) p. 715-728. Both IGF-I and GH have been claimed to stimulate the synthesis of IGFBP-3.

GH is used therapeutically to increase the growth of GH-deficient children, to improve muscle function and well-being in GH-deficient adults, to reduce the wasting in patients with AIDS, and to speed donor-site healing in burn patients. GH has been reported to be ineffective in impotence and to produce erectile insufficiency. Ra, S. et al., "In Vitro Contraction Of The Canine Corpus Cavernosum Penis By Direct Perfusion With Prolactin Or Growth Hormone," J. of Urology, 156, p. 522 (1996). GH has never been investigated for its reparative effects on pelvic parasympathetic nerves damaged by surgery or other conditions known to adversely affect parasympathetic nerves such as diabetes, alcoholism and aging.

GH may be useful *in vivo* to prevent and/or treat erectile dysfunction that occurs after radical prostatectomy, radical cystectomy (removal of the urinary bladder) or other surgeries that may damage the pelvic parasympathetic nerves such as rectal and vascular. GH may be useful to treat other organic causes of erectile dysfunction. GH in
5 combination with an IGF, an IGF:IGFBP complex, or another growth factor may be more efficacious in treating erectile dysfunction.

Disclosure of the invention

10

In this description, the following terms are employed:

Corpora Cavernosa: Two erectile bodies in the penis. Filling these with blood produces the erection.

15

Cavernous nerve: The nerve that supplies the small arteries and erectile tissues within the penis. It carries the impulses from the brain to the penis to produce erection. Because of its close relation to the prostate, the cavernous nerve is often injured during prostate or bladder surgery. It also undergoes various degrees of degeneration in older
20 men, heavy alcoholism and patients with diabetes mellitus.

Dorsal nerve of the penis: The nerve located under the skin of the penis. It contains both sensory nerves and branches of the cavernous nerve.

25

Nitric oxide synthase (NOS): An enzyme that produces nitric oxide which is the principal neurotransmitter for penile erection. Histochemical staining of nitric oxide synthase is a convenient way to localize the erection nerves.

Pelvic ganglia: A collection of the bodies of nerve cells (neurons) in the pelvis that innervate the pelvic organs such as rectum, bladder, prostate, seminal vesicles and the penis.

- 5 **Intracavernous therapy:** Injection directly into one of the two erectile bodies of the penis, cavernosum, with a needle.

Intraurethral therapy: Application of the agent into the penis through the external end of the urethra.

10

Intracavernous trabeculae: The supporting structure inside the corpora cavernosa. The fibrous skeleton provides support to the smooth muscles and provides passage for the branches of the cavernous nerve and artery.

- 15 **Neurotrophic growth factors:** Factors that stimulate nerve growth such as nerve growth factor, neurotrophins, brain-derived neurotrophic factor, ciliary neurotrophic factor, fibroblast growth factors, and insulin-like growth factors.

- 20 The invention solves the problem of impotence secondary to pelvic surgery, pelvic injury, alcoholism, diabetes mellitus, aging, or any condition that irreversibly damages the penile nerves. Erectile dysfunction in older men of other causes may also be improved or reversed by the treatment referred above.

- 25 In experimental studies erectile dysfunction was produced in rats by cutting one of the cavernous nerves supplying the penis. GH was administered in a dose of 300 ug/day twice daily subcutaneously for 21 days in 14 rats. When studied after 3 months and compared to placebo, GH significantly improved the number of the parasympathetic nerves and the erectile function. The erectile function was measured as intracavernous
30 pressure during electrostimulation of the contralateral cavernous nerve. GH was shown

to have a specific effect on regeneration of the nerves responsible for the erectile response. GH significantly increased the number of nitric oxide synthase (NOS) positive nerves in the intracavernous trabeculae and the dorsal nerve of the penis. Further evidence showed that these increases were due to stimulation of parasympathetic nerve
5 fiber growth from the contralateral, unsevered penile nerves.

Since IGF-I levels were increased in the rats administered GH, it is likely that GH acts by stimulating IGF-I production. IGF-I is the mediator of many of the actions of GH and has been shown to stimulate regeneration of other types of nerves. Skottner, A.
10 et al., "Anabolic And Tissue Repair Functions Of Recombinant Insulin-like Growth Factor I," Acta Paediatrica Scandinavica. Supplement, 367, p. 63 (1990). Our study is the first that shows the beneficial effect of GH on the regeneration of the erection nerves specifically the parasympathetic, nitric oxide synthase-containing cavernous and dorsal nerves. Combination of GH with IGF-I (with or without an IGFBP) may give a
15 heightened response in view of their additive effects on growth of certain organs and body weight in rats. Combination of GH with other growth factors, neurotrophins, or cytokines may also be effective. Therapy will be given by the most effective mode such as systemically, intracavernously or intraurethrally, and for the most effective duration.

20 **Best Mode Of Carrying Out The Invention**

Administer GH systemically in a therapeutic concentration daily for a) 30 to 90 days or b) an effective course to be determined post radical prostate surgery, after any pelvic surgery or injury that damages the innervation of the erectile response, or once the
25 cause of impotence is determined.

What is Claimed Is:

5

1. A method for preventing or reversing erectile dysfunction that occurs as a result of radical pelvic surgery, diabetes mellitus, alcoholism, aging, or pelvic injury comprising administering an effective amount of a) GH, b) a synthetically modified GH, c) peptides capable of stimulating endogenous GH secretion, or d) compounds capable of
10 activating the GH receptor.

2. A method for preventing or reversing erectile dysfunction that occurs as a result of radical pelvic surgery, diabetes mellitus, alcoholism, aging, or pelvic injury comprising administering an effective amount of a) IGF-I or IGF-II, b) modified forms of
15 IGFs, or c) a compound capable of activating the IGF-I receptor or post receptor mechanism.

3. A method for preventing or reversing erectile dysfunction that occurs as a result of radical pelvic surgery, diabetes mellitus, alcoholism, aging, or pelvic injury comprising administering an effective amount of IGF-I or IGF-II or modified forms of
20 these in combination with one of the natural or modified IGF binding proteins in an effective molecular ratio.

4. A method for preventing or reversing erectile dysfunction that occurs as a result of radical pelvic surgery, diabetes mellitus, alcoholism, aging, or pelvic injury comprising administering an effective amount of any of the compounds in claim 1
25 combined with a) IGF-I or IGF-II, b) a modified form of IGF-I or IGF-II, or c) a compound capable of activating the IGF-I receptor or post receptor mechanism.

5. A method for preventing or reversing erectile dysfunction that occurs as a result of radical pelvic surgery, diabetes mellitus, alcoholism, aging, or pelvic injury comprising administering an effective amount of any of the compounds in claim 1
30

- 5 combined with a complex of IGF-I or IGF-H with one of its natural or modified binding proteins in an effective molecular ratio.
6. A method for preventing or reversing erectile dysfunction that occurs as a result of radical pelvic surgery, diabetes mellitus, alcoholism, aging or pelvic injury
- 10 comprising administering an effective amount of any of the compounds in claim 1 with an effective amount of another growth factor such as fibroblast growth factor, epidermal growth factor, transforming growth factor - alpha or beta, platelet-derived growth factor, or neurotropic growth factors.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/05978

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) : A61K 38/00, 38/03, 38/04, 38/18, 38/22, 38/27, 38/30 US CL : 514/2, 866; 930/120 According to International Patent Classification (IPC) or to both national classification and IPC														
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/2, 866; 930/120 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet.														
C. DOCUMENTS CONSIDERED TO BE RELEVANT														
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
X --- Y	US 4,988,675 A (FROESCH et al.) 29 JANUARY 1991, col. 2, lines 15-23, and col. 5, lines 30-47.	2 --- 1, 3-6												
Y	US 5,447,912 A (GERSTENBERG et al.) 05 September 1995, col. 1, lines 24-28, and 51-60, col. 3, lines 63-68, and col. 9, lines 34-49.	1, 3-6												
Y	MARTIN, J.B. Regulation of Growth Hormone Secretion, In Human Growth Hormone, Eds. S. Raiti and R.A. Tolman, Plenum Publishing Corporation, NY, NY. 1986. pages 303-323, especially page 312, Table 1.	1, 3-6												
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.														
<table border="0"><tr><td>* Special categories of cited documents:</td><td>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td></tr><tr><td>*A* document defining the general state of the art which is not considered to be of particular relevance</td><td>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td></tr><tr><td>*B* earlier document published on or after the international filing date</td><td>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td></tr><tr><td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td><td>*A* document member of the same patent family</td></tr><tr><td>*O* document referring to an oral disclosure, use, exhibition or other means</td><td></td></tr><tr><td>*P* document published prior to the international filing date but later than the priority date claimed</td><td></td></tr></table>			* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family	*O* document referring to an oral disclosure, use, exhibition or other means		*P* document published prior to the international filing date but later than the priority date claimed	
* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention													
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone													
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art													
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family													
O document referring to an oral disclosure, use, exhibition or other means														
P document published prior to the international filing date but later than the priority date claimed														
Date of the actual completion of the international search 24 APRIL 1998		Date of mailing of the international search report 07 AUG 1998												
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer JANET M. KERR Telephone No. (703) 308-0196												

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/05978

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SKOTTNER. A. et al. Anabolic and Tissue Repair Functions of Recombinant Insulin-Like Growth Factor I. Acta Paediatr. Scand [Suppl.]. 1990. Vol. 367. pages 63-66, especially pages 64 and 65.	1, 3-6
Y	HINTZ. R.L. The Somatomedin Binding Proteins. In Human Growth Hormone, Eds. S. Raiti and R.A. Tolman, Plenum Publishing Corporation, NY, NY. 1986. pages 553-561, especially page 554.	1, 3-6
Y	LUE. T.F. Physiology of Erection and Pathophysiology of Impotence. In Campbell's Urology, 6th Edition. 1992. pages 709-728, especially pages 717-721.	1, 3-6

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/05978

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, MEDLINE, EMBASE, BIOSIS, WPIDS, CAPLUS

search terms: growth hormone, GH, insulin-like growth factor, IGF, erectile dysfunction, penile dysfunction, impotence, impotent, vasoactive intestinal peptide, somatomedin, alpha-adrenergic, alpha-adrenoreceptor, D2-dopamine agonist, surgery, diabetes, aging, alcoholism, IGF-I, IGF-II, fibroblast growth factor, fgf, epidermal growth factor, egf, transforming growth factor, tgf, pelvic injury, platelet derived growth factor, pdgf, neurotropic growth factor, ngf